Shumei Kato

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards

Yu Fujiwara, Shumei Kato, Razelle Kurzrock

us, jp (code pays fourni par la source)

Prospective Phase II Trial of Cemiplimab Plus Gemcitabine in SWItch/Sucrose Nonfermentable-Altered Metastatic Pancreatic Ductal Adenocarcinoma

Shawn Abeynaike, Roberta Vezza Alexander, Christina Snider, In Hwan Park et autres

us (code pays fourni par la source)

IP62-28 FROM DNA TO DECISION: THE SYNERGY OF GERMLINE AND SOMATIC TESTING IN PROSTATE CANCER

Sarah M. Nielsen, Neal D. Shore, Emily M. Russell, Michelle Green et autres

TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations

Shawn Abeynaike, Roberta Vezza Alexander, Christina Snider, In Hwan Park et autres

us (code pays fourni par la source)

Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies

Umut Dişel, Shumei Kato, Aditya Shreenivas, Ayca Ersen Danyeli et autres

ABSTRACT Background High-grade gliomas are associated with dismal outcomes and have devastating neurologic sequelae. Standard-of-care surgery, radiation, and temozolomide yield a median survival of 14–16 months in patients with glioblastoma (GBM). Methods We report four patients with high-grade glioma (two with GBM; …

tr, us (code pays fourni par la source)

A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.

Rahul Atul Parikh, Benjamin Herzberg, Mark N. Stein, Shumei Kato et autres

161 Background: Progression to mCRPC is driven by numerous mechanisms including emergence of AR LBD mutations that reactivate the AR pathway and blunt response to hormone therapies including novel hormonal agents (NHA). MRT-2359, an orally bioavailable MGD that selectively degrades the translation …

us, gb, de (code pays fourni par la source)

PD-L2 Landscape and Correlation With Outcome: An Immunomic Analysis

Anannya Patwari, Daisuke Nishizaki, Taylor J. Jensen, Paul DePietro et autres

PURPOSE PD-L1 and PD-L2 are inhibitory ligands that interact with PD-1 receptors, enabling immune escape. Although PD-L1 has been extensively studied, much less is known about PD-L2. PD-L2 expression could lead to incomplete blockade of the PD-1 axis by anti–PD-L1 agents and …

us, nl (code pays fourni par la source)

CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists

Yuji Uehara, Daisuke Nishizaki, Yu Fujiwara, Hirotaka Miyashita et autres

BACKGROUND: CD40 is a T-cell co-stimulatory receptor targeted by next-generation immunotherapies. We conducted a pan-cancer transcriptome analysis of CD40, its ligand, and related immune markers to evaluate co-expression patterns and clinical outcomes. METHODS: We analyzed transcriptome data for CD40, its ligand, and …

us, jp, gb (code pays fourni par la source)

582 First-in-human phase 1/2 study of the integrin αvβ8-blocking antibody CRB-601 in patients with solid tumors

Abdul Rafeh Naqash, Amita Patnaik, Vivek Subbiah, Cesar A. Perez et autres

Background Increased transforming growth factor beta (TGFβ) signaling in the tumor microenvironment is associated with immune cell exclusion and poor clinical outcomes. CRB-601 is a humanized monoclonal antibody that targets integrin αvβ8, preventing activation of the latent TGFβ complex. In preclinical studies, …

us, gb (code pays fourni par la source)

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies

Trever G. Bivona, Tadashi Manabe, Hannah C. Bergo, Qingtian Li et autres

us, it, do, de (code pays fourni par la source)

B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades

Brigid Larkin, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee et autres

Immunotherapy has transformed cancer treatment and outcomes, although resistance mechanisms remain challenging, prompting exploration of additional immune targets, including B7-H3/CD276. Indeed, B7-H3/CD276's complex and contrasting functions mark it as a jack of all trades, challenging conventional classifications of immune markers. B7-H3/CD276 is …

us, fr (code pays fourni par la source)

Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy Combinations

Daisuke Nishizaki, Sharon H. Choi, Chinmayi Pandya, Suzanna Lee et autres

PURPOSE Cotargetable immune pathways for available immune checkpoint inhibitors (ICIs) may mediate response and mitigate resistance. Immune profiling may provide insights into potential immunotherapy combinations and guide ongoing clinical trials. This study investigated the transcriptomic expression and clinical implications of B- and …

us (code pays fourni par la source)